	Application Ma	Applicant(a)
Notice of Allowability	Application No.	Applicant(s)
	10/807,228	SOGABE ET AL.
	Examiner	Art Unit
	Elizabeth Slobodyansky, PhD	1652
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	plication. If not included not will be mailed in due course. THIS
1. This communication is responsive to <u>AF amendments 30 August 2005 &amp; 06 October 2005</u> .		
2. The allowed claim(s) is/are 24,29 and 30.		
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority un</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> </ul>		
2.   Certified copies of the priority documents have been received in Application No. 08/799,897.		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
<i>;</i>		
		•
Attachment(s)  1. Notice of References Cited (PTO-892)	5 Notice of Informal F	Patent Application (PTO-152)
Notice of Preferences Cited (PTO-092)     Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	
	Paper No /Mail Da	te .
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li> </ol>	7. Examiner's Amendo	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	ent of Reasons for Allowance
or biological material	9. ⊠ Other see attached	!.
·		
		•

Application/Control Number: 10/807,228

Art Unit: 1652

## **DETAILED ACTION**

The AF amendment filed August 30, 2005 amending claim 30 has been entered.

The corrected AF amendment filed October 6, 2005 amending claims 24, 29 and 30 has been entered.

The Declaration under 37 CFR 1.132 by Dr. Atsushi Sogabe filed August 30, 2005 has been entered.

The supplemental Declaration to correct "errors" statement (37 C.F.R. 1.175) filed October 6, 2005 has been entered.

Claims 24, 29 and 30 are pending and allowed.

## Response to Amendment

The Declaration under 37 CFR 1.132 by Dr. Atsushi Sogabe filed August 30, 2005 is sufficient to overcome the objection to the specification and the 112, 1<sup>st</sup> paragraph, new matter rejection of claim 30 made in the last Office action mailed July 7, 2005.

Dr. Atsushi Sogabe states the nucleotide sequence of SEQ ID NO: 2 contained typographical error, specifically Nucleotide 435 of SEQ ID NO:2 should be guanine (G) and not cysteine (C). Therefore, the codon at nucleotides 433-435 should be GAG not GAC. The deduced amino acid sequence of SEQ ID NO:1 correctly sets forth the amino acid encoded by nucleotides 433-435 as glutamine (Glu). Dr. Sogabe further states that the correct nucleotide sequence of SEQ ID NO;2 can be obtained by sequencing the

Art Unit: 1652

amidinohydrolase gene derived from *Alcaligenes faecalis* TE3581, which has deposit accession number FERM P-14237.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky, PhD whose telephone number is 571-272-0941. The examiner can normally be reached on M-F 10:00 - 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, PhD can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elizabeth Slobodyansky, PhD

Page 3

Primary Examiner Art Unit 1652

October 11, 2005